Investor Relations

Esperion Therapeutics, Inc. is a pharmaceutical company focused on developing and commercializing first-in-class, oral, low-density lipoprotein cholesterol (LDL-C) lowering therapies for the treatment of  patients with elevated LDL-C.

Esperion Therapeutics is a publicly traded company (since 2013) and is listed on the NASDAQ Global Select Market under the symbol ESPR.

Esperion Therapeutics (NASDAQ: ESPR) 4:00 PM ET on Sep 29, 2016
Last Price Change Open Day High 52-Week High
0.00    (0.000%) 0.00 N/A 30.41
Volume Previous Close Day Low 52-Week Low
N/A 13.51 N/A 9.58

View all »   RSSRecent Releases

Aug 4, 2016
Esperion Therapeutics Provides Bempedoic Acid Development Program Updates; Reports Second Quarter 2016 Financial Results

Jun 28, 2016
Esperion Therapeutics Provides Clinical Development and Regulatory Update for Bempedoic Acid